Finding Hidden Patient Populations With Unstructured Data
This article was originally published on Norstella’s website. As real-world data (RWD) evolves, the rise of unstructured data—from clinical notes to lab reports—is transforming how life sciences teams identify, understand, and engage with patients and providers. These data sources offer rich, contextual insights into patient experiences, disease progression, and physician decision-making that traditional structured datasets often miss. At […]
Market Access in 2026: Predictions on Policies, Contracting and AI
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read the first of this two-part series for key insights into the year ahead. 1. What’s the biggest challenge for manufacturers launching new products this year? Steve Callahan, Senior Director, Advisory & Insights: […]
Faster Insights or Faster Fail? How to Avoid the Misuse of Real-World Data with AI
As artificial intelligence (AI) transforms how life sciences organizations access and analyze real-world data (RWD), one challenge looms large: ensuring that these powerful tools are used appropriately. RWD can illuminate patient outcomes, accelerate research, and guide better decision-making—but only when it’s handled ethically, transparently, and within the boundaries of contractual and regulatory use. Here are some ways to […]
The R&D Implications of Market Access Complexity
Our latest research at Norstella strongly suggests that a highly dynamic market access situation in the U.S. is feeding back into upstream decisions around R&D strategy. We explored this topic in detail in a recent white paper, Working Backwards: Patient Access Strategy Is Now Guiding R&D. This article briefly summarizes the first half of the […]
Tracking the Real-World Impact of Payer Policies on Patient Outcomes
In today’s complex pharmaceutical landscape, a brand’s market access can no longer be judged solely by its coverage. Pharma leaders are under growing pressure not just to identify access barriers, but to prove their impact. They want the ability to link payer policy decisions to patient outcomes, as their payer strategies and competitive positioning depend […]
Pharma’s Real-World Data Dilemma: Strategic Asset or Wasted Resource?
This article was originally published in BioPharma Dive. Every day, patients are experiencing the life-changing impact of real-world data (RWD), and life sciences companies are feeling the business impact, too. RWD is no doubt helping pharma companies better understand the patient journey and get life-saving therapies to market faster, according to Norstella’s recent survey of […]
Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification
This article was originally published in Drug Channels. As patient access grows more complex, manufacturers need tools that reduce friction throughout the care journey. One valuable but frequently overlooked dataset is known as BIN/PCN/Group (BPG) data, which refers to a trio of identifiers used in pharmacy claims processing. Unlocking the power of BPG data can […]
Drive HCP Engagement with Smarter Omnichannel Marketing
Pharma companies have made significant strides in omnichannel marketing, building programs that engage healthcare professionals (HCPs) across email, digital, social, and peer-to-peer platforms. However, many of these campaigns are often based on static HCP lists and pre-scheduled sequencing, leaving brand teams unable to adapt to clinical events as they occur. Real-world data (RWD) changes that […]
GenAI and RWD in Pharma: 4 Questions to Fuel Effective Insights
This article was originally published in BioPharma Dive. Generative AI (GenAI) has become one of the most talked-about innovations in healthcare analytics, but for life sciences organizations, simply deploying an AI-powered solution is not enough. To truly unlock the power of real-world data (RWD), GenAI must go beyond checking a box or riding the latest […]
Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization
This article was originally published in Drug Channels. To chart a clear path to commercialization, a manufacturer must begin with the end in mind. Early market research helps pharma companies understand which clinical endpoints and differentiators an asset will need to succeed at launch. Today, one-third of pharma companies start market access planning in Phase I, and […]